Evidence map›Paper›PMID 39195920›Full record

ArticleNature cardiovascular research2023

The VE-cadherin/AmotL2 mechanosensory pathway suppresses aortic inflammation and the formation of abdominal aortic aneurysms.

Yuanyuan Zhang, Yumeng Zhang, Evelyn Hutterer, Sara Hultin, Otto Bergman, Solrun Kolbeinsdottir, Hong Jin, Maria J Forteza, Daniel F J Ketelhuth, Joy Roy and 5 more

Abstract read
In one paragraph

Article in Nature cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Emerging Mechanisms of Abdominal Aortic Aneurysm.Current atherosclerosis reports · 2026
    Review
  2. Article
  3. Review
  4. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells.Journal of experimental & clinical cancer research : CR · 2024
    Article
  5. Regulation of YAP Promotor Accessibility in Endothelial Mechanotransduction.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuanyuan ZhangDepartment of Oncology-Pathology, BioClinicum, Karolinska Institutet, Stockholm, Sweden.
Yumeng ZhangDepartment of Oncology-Pathology, BioClinicum, Karolinska Institutet, Stockholm, Sweden.
Evelyn HuttererDepartment of Oncology-Pathology, BioClinicum, Karolinska Institutet, Stockholm, Sweden.
Sara HultinDepartment of Oncology-Pathology, BioClinicum, Karolinska Institutet, Stockholm, Sweden.
Otto BergmanDepartment of Medicine Solna, BioClinicum, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Solrun KolbeinsdottirDepartment of Oncology-Pathology, BioClinicum, Karolinska Institutet, Stockholm, Sweden.
Hong JinDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-8878-6436
Maria J FortezaDepartment of Medicine Solna, BioClinicum, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Daniel F J KetelhuthDepartment of Medicine Solna, BioClinicum, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Joy RoyDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Ulf HedinDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Martin EngeDepartment of Oncology-Pathology, BioClinicum, Karolinska Institutet, Stockholm, Sweden.
Ljubica MaticDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-7294-9667
Per ErikssonDepartment of Medicine Solna, BioClinicum, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Lars HolmgrenDepartment of Oncology-Pathology, BioClinicum, Karolinska Institutet, Stockholm, Sweden. lars.holmgren@ki.se.ORCID 0000-0001-6227-2181

Funding

Hjärt-Lungfonden (Swedish Heart-Lung Foundation) 20200531Hjärt-Lungfonden (Swedish Heart-Lung Foundation) 20210466Hjärt-Lungfonden (Swedish Heart-Lung Foundation) K711001393Novo Nordisk Fonden (Novo Nordisk Foundation) 0064142Novo Nordisk Fonden (Novo Nordisk Foundation) NNF15CC0018346Novo Nordisk Fonden (Novo Nordisk Foundation) NNF15SA0018346Svenska Forskningsrådet Formas (Swedish Research Council Formas) 2021-01516Vetenskapsrådet (Swedish Research Council) 2019-02027
6 · The paper itself

Abstract

Endothelial cells respond to mechanical forces exerted by blood flow. Endothelial cell-cell junctions and the sites of endothelial adhesion to the matrix sense and transmit mechanical forces to the cellular cytoskeleton. Here we show that the scaffold protein AmotL2 connects junctional VE-cadherin and actin filaments to the nuclear lamina. AmotL2 is essential for the formation of radial actin filaments and the alignment of endothelial cells, and, in its absence, nuclear integrity and positioning are altered. Molecular analysis demonstrated that VE-cadherin binds to AmotL2 and actin, resulting in a cascade that transmits extracellular mechanical signals to the nuclear membrane. Furthermore, the endothelial deficit of AmotL2 in mice fed normal diet provoked a pro-inflammatory response and abdominal aortic aneurysms (AAAs). Transcriptome analysis of human AAA samples revealed a negative correlation between AmotL2 and inflammation of the aortic intima. These findings offer insight into the link between junctional mechanotransduction and vascular disease.

Indexed as

Antigens, CDAortic Aneurysm, AbdominalCadherinsMechanotransduction, CellularActin CytoskeletonActinsAngiomotinsAnimalsAorta, AbdominalAortitisCadherin 5Disease Models, AnimalEndothelial CellsHumansHuman Umbilical Vein Endothelial CellsMaleActinsAMOTL2 protein, humanAngiomotinsAntigens, CDCadherin 5Cadherins

Identifiers

PMID39195920
PMCPMC11358041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.